Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for fatty liver cirrhosis in early trial

NCT ID NCT06465186

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 1 time

Summary

This study tests an experimental drug called efinopegdutide in 80 adults with liver scarring (cirrhosis) caused by metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. The goal is to see if the drug can reduce liver fat, inflammation, and scarring over about 7 months, while also checking for side effects. Participants receive either the drug or a placebo, and neither they nor their doctors know which they get.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

85 people

The number who actually took part.

Started

Jul 2024

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) * Has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has history of a liver disease other than MASH, for example, Hepatitis B or C, drug-induced liver disease, or autoimmune liver disease * Has history of type 1 diabetes * Had a bariatric surgical procedure less than 5 years before entry into the study * History of pancreatitis * Major illnesses like recent (within 6 months of study entry) episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction-associated steatohepatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction-associated steatohepatitis Metabolic dysfunction-associated steatotic liver disease NAFLD Non-alcoholic fatty liver disease Nonalcoholic steatohepatitis

Contacts and locations

Locations

  • Aberdeen Royal Infirmary-Department of Gastroenterology ( Site 1102)

    Aberdeen, Scotland, AB25 2ZN, United Kingdom

  • Acclaim Clinical Research ( Site 0137)

    San Diego, California, 92120, United States

  • American Research Corporation ( Site 0131)

    San Antonio, Texas, 78215, United States

  • Arizona Clinical Trials ( Site 0158)

    Flagstaff, Arizona, 86001, United States

  • Assuta Medical Center ( Site 0806)

    Tel Aviv, 6789140, Israel

  • CHU Bordeaux Haut-Leveque-Service d'Hépato-gastroentérologie ( Site 0701)

    Pessac, Aquitaine, 33600, France

  • CHUAC-Complejo Hospitalario Universitario A Coruña-Endocrinología ( Site 1007)

    A Coruña, La Coruna, 15006, Spain

  • CHUS - Hospital Clinico Universitario ( Site 1011)

    Santiago de Compostela, La Coruna, 15706, Spain

  • California Liver Research Institute ( Site 0113)

    Pasadena, California, 91105, United States

  • Carmel Hospital-Liver Unit ( Site 0802)

    Haifa, 3436212, Israel

  • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren-Hépato-gastroentérologie ( Site 0702)

    Limoges, Limousin, 87042, France

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Pôle de Référence Hépato Gastro-entérol ( Site 0704)

    Nice, Alpes-Maritimes, 06202, France

  • Chulalongkorn University ( Site 1301)

    Bangkok, Bangkok, 10330, Thailand

  • Coastal Research Institute - Fayetteville ( Site 0159)

    Fayetteville, North Carolina, 28304, United States

  • Delta Research Partners ( Site 0160)

    Bastrop, Louisiana, 71220, United States

  • Diex Recherche Quebec ( Site 0204)

    Québec, Quebec, G1V 4T3, Canada

  • Excel Clinical Research, LLC ( Site 0101)

    Las Vegas, Nevada, 89109, United States

  • Faculty of Medicine Siriraj Hospital-Department of Medicine ( Site 1302)

    Bangkok, Bangkok, 10700, Thailand

  • Flinders Medical Centre-Hepatology and Liver Transplant Medicine ( Site 1202)

    Adelaide, South Australia, 5042, Australia

  • Florida Research Institute ( Site 0116)

    Lakewood Rch, Florida, 34211, United States

  • Floridian Clinical Research, LLC ( Site 0109)

    Miami Lakes, Florida, 33016, United States

  • Fundacion Santa Fe de Bogota ( Site 0403)

    Bogotá, Cundinamarca, 110111, Colombia

  • Fundación Valle del Lili ( Site 0402)

    Cali, Valle del Cauca Department, 760032, Colombia

  • GI Alliance Department of Research ( Site 0162)

    Fort Worth, Texas, 76104, United States

  • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Unidad de Ensayos clinicos de Aparato Digestivo ( Site 1001)

    Seville, 41013, Spain

  • Homestead Associates in Research, Inc. ( Site 0139)

    Homestead, Florida, 33033, United States

  • Hospital Clínico Universitario de Valladolid-Servicio de Endocrinologia y Nutricion ( Site 1008)

    Valladolid, Castille and León, 47010, Spain

  • Hospital General de Tomelloso-Aparato Digestivo ( Site 1006)

    Tomelloso, Ciudad Real, 13700, Spain

  • Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 1002)

    Barcelona, 08035, Spain

  • Hospital Universitario La Paz-HEPATOLOGIA ( Site 1005)

    Madrid, 28046, Spain

  • Hospital Universitario Marqués de Valdecilla-Gastroenterology and Hepatology ( Site 1004)

    Santander, Cantabria, 39005, Spain

  • Houston Research Institute ( Site 0117)

    Houston, Texas, 77079, United States

  • Houston Research Institute ( Site 0172)

    Houston, Texas, 77004, United States

  • Huron Gastroenterology ( Site 0102)

    Ypsilanti, Michigan, 48197, United States

  • Hôpital Beaujon-Hépatologie ( Site 0703)

    Clichy, Hauts-de-Seine, 92110, France

  • Hôpital de la Croix Rousse-Centre de Recherche Clinique ( Site 0705)

    Lyon, Auvergne-Rhône-Alpes, 69004, France

  • ISIS CLINICAL RESEARCH CENTER ( Site 0606)

    Guaynabo, 00968, Puerto Rico

  • King's College Hospital ( Site 1104)

    London, London, City of, SE5 9RL, United Kingdom

  • Klinical Investigations Group-Clinical Research ( Site 0601)

    San Juan, 00909, Puerto Rico

  • Louisiana Research Center ( Site 0161)

    Shreveport, Louisiana, 71105, United States

  • Lucas Research, Inc ( Site 0105)

    Morehead City, North Carolina, 28557, United States

  • Maccabi Health Services - Petah Tikva ( Site 0804)

    Petah Tikva, 4925110, Israel

  • Osaka Metropolitan University Hospital ( Site 1403)

    Osaka, 545-8586, Japan

  • Pinnacle Clinical Research ( Site 0104)

    Austin, Texas, 78757, United States

  • Pinnacle Clinical Research-Clinical Research Coordination ( Site 0125)

    San Antonio, Texas, 78229, United States

  • Pinnacle Clinical Research-Corpus Christi ( Site 0156)

    Corpus Christi, Texas, 78404, United States

  • Rambam Health Care Campus ( Site 0801)

    Haifa, 3109601, Israel

  • Rocky Mountain Gastroenterology ( Site 0127)

    Littleton, Colorado, 80120, United States

  • Saga University Hospital ( Site 1405)

    Saga, 849-8501, Japan

  • Shaare Zedek Medical Center ( Site 0805)

    Jerusalem, 9103102, Israel

  • Shinyurigaoka General Hospital ( Site 1401)

    Kawasaki, Kanagawa, 215-0026, Japan

  • Southeast Clinical Research Center ( Site 0119)

    Dalton, Georgia, 30720, United States

  • Southwest Gastroenterology Associates ( Site 0129)

    Albuquerque, New Mexico, 87109, United States

  • St Vincent's Hospital-Gastroenterology Department ( Site 1205)

    Melbourne, Victoria, 3065, Australia

  • Synergy Healthcare ( Site 0118)

    Bradenton, Florida, 34209, United States

  • Texas Clinical Research Institute ( Site 0126)

    Arlington, Texas, 76012, United States

  • The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0149)

    Chandler, Arizona, 85224, United States

  • The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0120)

    Peoria, Arizona, 85381, United States

  • The Institute for Liver Health II dba Arizona Liver Health-Tucson ( Site 0111)

    Tucson, Arizona, 85712, United States

  • The Machuca Foundation ( Site 0115)

    Las Vegas, Nevada, 89101, United States

  • Toronto General Hospital ( Site 0207)

    Toronto, Ontario, M5G 2C4, Canada

  • University Hospital,Kyoto Prefectural University of Medicine ( Site 1404)

    Kyoto, 602-8566, Japan

  • University of Virginia Health System ( Site 0164)

    Charlottesville, Virginia, 22908, United States

  • Velocity Clinical Research Rockville ( Site 0143)

    Rockville, Maryland, 20854, United States

  • Velocity Clinical Research, Panorama City ( Site 0124)

    Van Nuys, California, 91405, United States

  • Woodholme Gastroenterology Associates-Woodholme Gastroenterology Associates ( Site 0130)

    Glen Burnie, Maryland, 21061, United States

  • Yokohama City University Hospital ( Site 1402)

    Yokohama, Kanagawa, 236-0004, Japan

  • Zenos Clinical Research ( Site 0136)

    Dallas, Texas, 75230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.